GPX4 activator enhances neuroprotection and functional recovery in spinal cord injury

Xinjie Liu, Yilin Pang, Baoyou Fan, Jiawei Zhang, Shen Liu, Xiaobing Deng, Jin Li, Ying Liu, Xu Zhang, Chenxi Zhao, Xiaoyu Wang, X. Wu, Luhua Lai, Shiqing Feng, Wenpeng Liu, Guangzhi Ning, Xue YaoJournal of Orthopaedic Translation 2025 · DOI

TL;DR

Spinal cord injury (SCI) leads to significant functional loss, and current treatments are limited. This study reveals that the ferroptosis regulator GPX4 is downregulated in neurons after SCI, contributing to neuronal death and inflammation. Importantly, activating GPX4 with a novel small molecule significantly improves functional recovery by protecting neurons and reducing inflammation, offering a promising therapeutic avenue.

What Problem Does This Paper Address?

Spinal cord injury (SCI) is a devastating condition that results in profound sensory and motor deficits, leading to significant personal and societal burdens. While the immediate mechanical damage is a primary injury, a cascade of secondary injury events, including inflammation and oxidative stress, exacerbates the damage over time. One critical process implicated in SCI pathogenesis is ferroptosis, a form of programmed cell death characterized by iron-dependent lipid peroxidation. Glutathione peroxidase 4 (GPX4) is a key enzyme that regulates ferroptosis by detoxifying lipid hydroperoxides. However, the precise role of GPX4 in SCI and the therapeutic potential of targeting it remain poorly understood. This paper aims to elucidate the temporal and spatial expression of GPX4 in SCI, investigate its role in neuronal ferroptosis and subsequent neuroinflammation, and evaluate the efficacy of a GPX4 activator in promoting functional recovery.

Methods

The researchers employed a multi-faceted approach to investigate GPX4's role in SCI:

  • SCI Model: A T10 contusion SCI model was established in Wistar rats.
  • GPX4 Expression Analysis: Western blotting and immunofluorescence staining were used to track GPX4 protein levels and localization in spinal cord tissue at various time points post-injury and in different cell types (neurons, oligodendrocytes, microglia, astrocytes).
  • Ferroptosis Induction: In vitro experiments used primary cortical neurons treated with RSL-3, a known GPX4 inhibitor, to induce ferroptosis.
  • Inflammation Assessment: RNA-sequencing (RNA-Seq) was performed on neurons treated with RSL-3 to identify differentially expressed genes related to inflammatory pathways. Conditioned media from these ferroptotic neurons were then applied to BV-2 microglia to assess their activation.
  • GPX4 Activation: A novel small molecule, PKUMDL-LC-102, identified as an allosteric GPX4 activator, was administered to SCI rats.
  • Functional Recovery Assessment: A battery of behavioral tests, including the Basso, Beattie, and Bresnahan (BBB) score, Catwalk gait analysis, grid-walk test, and Louisville swim scale (LSS), were used to evaluate motor function.
  • Electrophysiology: Motor-evoked potentials (MEPs) were measured to assess the functional integrity of motor pathways.
  • Neuroimaging: Sagittal T2-weighted MRI was used to assess lesion size and severity.
  • Pharmacokinetics and Safety: The absorption, distribution, metabolism, and excretion (ADME) of the GPX4 activator were studied, along with its potential toxicity to the liver and kidneys.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • GPX4 is a neuronal protector in SCI: The study firmly establishes GPX4 as a critical factor in neuronal survival following SCI. Its downregulation directly correlates with increased ferroptosis and neuronal loss.
  • Ferroptosis fuels neuroinflammation: The research highlights a crucial link between ferroptosis and neuroinflammation. Neuronal ferroptosis, triggered by GPX4 inhibition, leads to the release of pro-inflammatory cytokines, which in turn activate microglia. This suggests that targeting ferroptosis could be a dual-action therapeutic strategy.
  • A novel GPX4 activator offers therapeutic promise: The development and successful application of PKUMDL-LC-102, a small molecule GPX4 activator, represent a significant advancement. This activator works by enhancing the enzymatic activity of existing GPX4, rather than increasing its expression, offering a potentially more direct and efficient therapeutic approach.
  • Targeted activation is key: Unlike broader ferroptosis inhibitors, this study focuses on specifically activating GPX4, suggesting a more precise and potentially safer therapeutic strategy.

Key Results

  • GPX4 downregulation post-SCI: GPX4 expression was significantly reduced in neurons in the acute and subacute phases following SCI.
  • GPX4 inhibition induces ferroptosis and inflammation: In vitro, RSL-3 treatment of neurons led to ferroptosis, increased pro-inflammatory cytokine expression, and activated microglia.
  • GPX4 activator improves functional recovery: Administration of PKUMDL-LC-102 to SCI rats resulted in:
  • Significant improvements in BBB scores, gait analysis, grid-walk tests, and Louisville swim scale scores.
  • Enhanced motor-evoked potential amplitudes.
  • Reduced lesion area and T2 hypointensity on MRI.
  • Increased neuronal survival and reduced microgliosis in the injured spinal cord.
  • GPX4 activator is safe: The GPX4 activator showed favorable pharmacokinetics with a rapid plasma increase and a short half-life, and importantly, did not induce significant liver or kidney toxicity in rats.

Limitations and Future Work

  • Isoform specificity: The study acknowledges that GPX4 has distinct isoforms, and while cytosolic expression in neurons and nuclear expression in oligodendrocytes were observed, the specific roles of each isoform were not differentiated. Future research could explore isoform-specific targeting.
  • Neuron-microglia crosstalk mechanisms: While a neuron-microglia crosstalk mediated by GPX4 was suggested, the precise molecular mechanisms underlying this interaction require further investigation.
  • Delivery optimization: The authors mention the need for further optimization of drug delivery, potentially through nanoparticle strategies, to enhance the efficiency of the GPX4 activator.
  • Broader therapeutic potential: The findings suggest that GPX4 activation could be beneficial for other CNS disorders involving ferroptosis, such as neurodegenerative diseases, traumatic brain injury, and experimental autoimmune encephalomyelitis (EAE), warranting further investigation in these contexts.

Summary updated

Abstract

These findings provide a novel avenue for therapeutic intervention to enhance functional recovery after SCI through GPX4 targeted activation.
BibTeX
@article{liu2025gpx,
  author = {Xinjie Liu and Yilin Pang and Baoyou Fan and Jiawei Zhang and Shen Liu and Xiaobing Deng and Jin Li and Ying Liu and Xu Zhang and Chenxi Zhao and Xiaoyu Wang and X. Wu and Luhua Lai and Shiqing Feng and Wenpeng Liu and Guangzhi Ning and Xue Yao},
  title = {{GPX4 activator enhances neuroprotection and functional recovery in spinal cord injury}},
  journal = {Journal of Orthopaedic Translation},
  year = {2025},
  doi = {10.1016/j.jot.2025.03.013},
}
Figure